Lipids have long been used as drug delivery vehicles, but HighField Biopharmaceutics is repurposing lipids as drugs to fight cancer. The company’s technology platform is seeking to change the immunotherapy landscape with new treatments that are better targeted, more potent, and less toxic. We spoke to Don Wyatt, chief business officer for HighField Biopharmaceuticals, about the tumor microenvironment, HighField’s platform technology, and how it is developing lipid-based medicines to overcome challenges of existing immunotherapies.
Teaching an Old Drug a New Trick to Prevent Lyme Disease
A New Class of Cell Therapies to Target Solid Tumors
A Company Born from a Father Who Wore His Heart on His Sleeve
Using AI to Improve Burn Care
A Home for Biotech in the City that Never Sleeps
Biopharma R&D Growing Stronger
The Benefits of Having a Multitude of Cins
Making ADCs Smarter and Safer with a Simple Twist of Fate
Targeting a Natural Repair System to Restore Brain Health
Programing Cells in a Predictable and Scalable Way
Why DNA May Be the Data Storage Medium of the Future
Scouring Genetic Variation within Our Cells for Drug Targets
Correcting Gene Dysregulation to Treat Diseases
Using Technology to Regain Abilities after Spinal Cord Injury
Why Drug Developers Have a Growing Interest in Targeting Mitochondria
Beefing Up Computational Muscle to Understand Molecular Activity of Drug Candidates
Targeting a Multitude of CIN in Cancer Cells
The Year in Biotech and What’s Ahead in 2024
Transforming Healthcare with Data
Create your
podcast in
minutes
It is Free
DNA Today: A Genetics Podcast
Short Wave
Stuff To Blow Your Mind
Unexplainable
Speaking of Psychology